【藥品庫存】 本藥品為臨時採購藥品，經院長核可後，限定特定科別、病人使用。

Onchocerciasis, strongyloidiasis
Off-label use: Scabies, ascariasis, demodicosis, gnathostomiasis, Hookworm-related cutaneous larva migrans, Lice

Anthelmintic
A semisynthetic anthelminthic agent which binds selectively and with strong affinity to glutamate-gated chloride ion channels which occur in invertebrate nerve and muscle cells. This leads to increased permeability of cell membranes to chloride ions then hyperpolarization of the nerve or muscle cell, and death of the parasite.

Absorption
Well absorbed in the fasting state; may be increased with a high-fat meal
Distribution
1. Vd 3.1-3.5 L/kg in healthy volunteers; mean Vd 9.9 L/kg (range: 6.9 to 15.3 L/kg) in patients with onchocerciasis
2. High concentration in the liver and adipose tissue; does not readily cross the blood-brain barrier
3. Protein binding: ~93% primarily to albumin
Metabolism
Hepatic via CYP3A4 (major), CYP2D6 (minor), and CYP2E1 (minor)
Excretion
Feces; urine (<1%)
Pharmacodynamics
1. Half-life elimination: 18 hours
2. Time to peak, serum: ~4 hours

Hypersensitivity to ivermectin or any component of the formulation

The decision to use ivermectin during pregnancy should consider the specific indication (eg, onchocerciasis or Strongyloides infection) and the risk of disease progression in the absence of treatment. Although use in pregnancy is likely low risk, other agents are currently recommended for the treatment of pediculosis pubis or scabies in pregnant women.

The decision to use ivermectin in a patient who is breastfeeding should consider the specific indication (eg, onchocerciasis or Strongyloides infection) and the risk of disease progression in the absence of treatment.

>10%: Pruritus, dermatological reaction, lymphadenitis, arthralgia, synovitis, fever
1-10%: Tachycardia, peripheral edema, facial edema, orthostatic hypotension, dizziness, diarrhea, nausea, eosinophilia, decreased white blood cell count, increased hemoglobin, increased ALT or AST

Onchocerciasis: 150 mcg/kg as a single dose; retreatment may be required every 3-12 months until asymptomatic
Strongyloidiasis, intestinal: 200 mcg/kg/day for 1-2 days

1. Weight-band dosing to provide 150 mcg/kg
15-25: 3 mg
26-44: 6 mg
45-64: 9 mg
65-84: 12 mg
≥85: 150 mcg/kg
2. Weight-band dosing to provide 200 mcg/kg
15-24: 3 mg
25-35: 6 mg
36-50: 9 mg
51-65: 12 mg
66-79: 15 mg
≥80: 200 mcg/kg

There are no dosage adjustments provided in manufacturer's labeling.

There are no dosage adjustments provided in manufacturer's labeling

Store at room temperature below 30 degree C